Pfizer will hold a meeting of the Board of Directors of the Company on 26 October 2019.

Powered by Capital Market - Live News

Net profit of Pfizer rose 22.83% to Rs 112.81 crore in the quarter ended June 2019 as against Rs 91.84 crore during the previous quarter ended June 2018. Sales rose 6.26% to Rs 544.40 crore in the quarter ended June 2019 as against Rs 512.31 crore during the previous quarter ended June 2018.

Powered by Capital Market - Live News

Mylan N.V. and Pfizer announced a definitive agreement tocombine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company.

Under the terms of the agreement,which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would beconverted into one share of the new company. Pfizer shareholders would own 57% of thecombined new company, and Mylan shareholders would own 43%. The Boards of Directors ofboth Mylan and Pfizer have unanimously approved the transaction.

The new company will transform and accelerate each businesses' ability to serve patients'needs and expand their capabilities across more than 165 markets by bringing together twohighly complementary businesses. Mylan brings a diverse portfolio across many geographiesand key therapeutic areas, such as central nervous system and anesthesia, infectious diseaseand cardiovascular, as well as a robust pipeline, high-quality manufacturing and supply chainexcellence. Upjohn brings trusted, iconic brands, such as Lipitor (atorvastatin calcium), Celebrex(celecoxib) and Viagra (sildenafil), and proven commercialization capabilities, includingleadership positions in China and other emerging markets.

The transaction will allow the new company to meaningfully expand the geographic reach ofMylan's existing broad product portfolio and future pipeline - including significant investmentsthat have been made across complex generics and biosimilars - into new growth markets whereUpjohn has existing sales infrastructure and local market expertise.

Powered by Capital Market - Live News

Pfizer will hold a meeting of the Board of Directors of the Company on 9 August 2019.

Powered by Capital Market - Live News